Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?

BMC Cancer

Robert U Newton²  Dennis R Taaffe⁴  Nigel Spry⁵  Prue Cormie²  Suzanne K Chambers³  Robert A Gardiner¹  David HK Shum³  David Joseph⁵  Daniel A Galvão² 

[1] Centre for Clinical Research at Royal Brisbane Hospital, The University of Queensland, Brisbane, QLD, Australia

[2] Edith Cowan University Health and Wellness Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, Western Australia 6027, Australia

[3] Behavioural Basis of Health Program, Griffith Health Institute, Griffith University, Brisbane, QLD, Australia

[4] School of Human Movement Studies, The University of Queensland, Brisbane, QLD, Australia

[5] Faculty of Medicine, University of Western Australia, Nedlands, WA, Australia

关键词: Side-effects;    Aerobic training;    Resistance training;    Exercise;    Androgen deprivation therapy;    Prostate cancer;   

Others  :  1080177
DOI  :  10.1186/1471-2407-12-432

 received in 2012-08-27, accepted in 2012-09-20,  发布年份 2012

【 摘 要 】

Background

There has been substantial increase in use of androgen deprivation therapy as adjuvant management of prostate cancer. However, this leads to a range of musculoskeletal toxicities including reduced bone mass and increased skeletal fractures compounded with rapid metabolic alterations, including increased body fat, reduced lean mass, insulin resistance and negative lipoprotein profile, increased incidence of cardiovascular and metabolic morbidity, greater distress and reduced quality of life. Numerous research studies have demonstrated certain exercise prescriptions to be effective at preventing or even reversing these treatment toxicities. However, all interventions to date have been of rehabilitative intent being implemented after a minimum of 3 months since initiation of androgen deprivation, by which time considerable physical and psychological health problems have manifested. The pressing question is whether it is more efficacious to commence exercise therapy at the same time as initiating androgen deprivation, so treatment induced adverse effects can be immediately attenuated or indeed prevented.

Methods/design

We are proposing a multi-site randomized controlled trial with partial crossover to examine the effects of timing of exercise implementation (immediate or delayed) on preserving long-term skeletal health, reversing short- and long-term metabolic and cardiovascular risk factors, and supporting mental health in men receiving androgen deprivation therapy. 124 men who are about to initiate androgen deprivation for prostate cancer will be randomized to immediate or delayed groups. Immediate will commence a 6-month exercise program within 7–10 days of their first dose. Delayed will receive usual care for 6 months and then commence the exercise program for 6 months (partial cross-over). Immediate will be free to adopt the lifestyle of their choosing following the initial 6-month intervention. Measurements for primary and secondary endpoints will take place at baseline, 6 months and 12 months.

Discussion

This project is unique as it explores a fundamental question of when exercise implementation will be of most benefit and addresses both physical and psychological consequences of androgen deprivation initiation. The final outcome may be adjunct treatment which will reduce if not prevent the toxicities of androgen deprivation, ultimately resulting in reduced morbidity and mortality for men with prostate cancer.

Trial registration

ACTRN12612000097842

【 授权许可】

   
2012 Newton et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 4.

【 参考文献 】

• [1]Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS: Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 2005, 103(8):1615-1624.
• [2]Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, et al.: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005, 6(11):841-850.
• [3]Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106.
• [4]Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7(6):472-479.
• [5]McCredie M, Cox B: Prostate-specific antigen testing for prostate cancer: the case for informed consent. Med J Aust 1998, 169(1):9-10.
• [6]Moul JW: Prostate specific antigen only progression of prostate cancer. J Urol 2000, 163(6):1632-1642.
• [7]Shahinian VB, Kuo YF, Freeman JL, Goodwin JS: Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352(2):154-164.
• [8]Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL: Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23(31):7897-7903.
• [9]Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C: Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003, 104(2):195-201.
• [10]Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001, 86(9):4261-4267.
• [11]Smith MR, Lee H, Fallon MA, Nathan DM: Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 2008, 71(2):318-322.
• [12]Smith MR, Lee H, Nathan DM: Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91(4):1305-1308.
• [13]Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87(2):599-603.
• [14]Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 2006, 24(24):3979-3983.
• [15]Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R: Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 2008, 102(1):44-47.
• [16]Keating NL, O’Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24(27):4448-4456.
• [17]Keating NL, O’Malley AJ, Freedland SJ, Smith MR: Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer. J Natl Cancer Inst 2010, 102(1):39-46.
• [18]Tsai HK, D’Amico AV, Sadetsky N, Chen MH, Carroll PR: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99(20):1516-1524.
• [19]Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007, 110(7):1493-1500.
• [20]D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, et al.: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25(17):2420-2425.
• [21]Chambers SK, Lynch BM, Aitken J, Baade P: Relationship over time between psychological distress and physical activity in colorectal cancer survivors. J Clin Oncol 2009, 27(10):1600-1606.
• [22]Green HJ, Pakenham KI, Headley BC, Yaxley J, Nicol DL, Mactaggart PN, Swanson CE, Watson RB, Gardiner RA: Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 2004, 93(7):975-979.
• [23]Spry NA, Kristjanson L, Hooton B, Hayden L, Neerhut G, Gurney H, Corica T, Korbel E, Weinstein S, McCaul K: Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer 2006, 42(8):1083-1092.
• [24]Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU: Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 2010, 28(2):340-347.
• [25]Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, Yamaya K, McGuigan MR, Kristjanson LJ, Newton RU: Endocrine and immune responses to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis 2008, 11(2):160-165.
• [26]Galvão DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU: Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 2006, 38(12):2045-2052.
• [27]Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D’Angelo ME, et al.: Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2003, 21(9):1653-1659.
• [28]Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud’Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D’Angelo ME: Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 2009, 27(3):344-351.
• [29]Galvao DA, Newton RU: Review of exercise intervention studies in cancer patients. J Clin Oncol 2005, 23(4):899-909.
• [30]Alibhai SM, Breunis H, Timilshina N, Johnston C, Tomlinson G, Tannock I, Krahn M, Fleshner NE, Warde P, Canning SD, et al.: Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol 2010, 28(34):5038-5045.
• [31]Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU: Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response. J Urol 2011, 186(4):1291-1297.
• [32]Galvão DA, Spry N, Taaffe DR, Denham J, Joseph D, Lamb DS, Levin G, Duchesne G, Newton RU: A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial. BMC Cancer 2009, 9:419-419. BioMed Central Full Text
• [33]Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, Joseph D, Chambers SK, Galvao DA: A phase III clinical trial of exercise modalities on treatment side-effects in men receiving therapy for prostate cancer. BMC Cancer 2009, 9:210. BioMed Central Full Text
• [34]Galvao DA, Taaffe DR, Cormie P, Spry N, Chambers SK, Peddle-McIntyre C, Baker M, Denham J, Joseph D, Groom G, et al.: Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer 2011, 11:517. BioMed Central Full Text
• [35]Hamilton EJ, Ghasem-Zadeh A, Gianatti E, Lim-Joon D, Bolton D, Zebaze R, Seeman E, Zajac JD, Grossmann M: Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy. J Clin Endocrinol Metab 2010, 95(12):E456-E463.
• [36]Taaffe DR, Duret C, Wheeler S, Marcus R: Once-weekly resistance exercise improves muscle strength and neuromuscular performance in older adults. J Am Geriatr Soc 1999, 47(10):1208-1214.
• [37]Galvão DA, Taaffe DR: Resistance exercise dosage in older adults: single- versus multiset effects on physical performance and body composition. J Am Geriatr Soc 2005, 53(12):2090-2097.
• [38]Plasqui G, Westerterp KR: Physical activity assessment with accelerometers: an evaluation against doubly labeled water. Obesity 2007, 15(10):2371-2379.
• [39]Ajzen I: The theory of planned behavior. Organ Behav Hum Decis Process 1991, 50(2):179-211.
• [40]Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376.
• [41]Roth AJ, Rosenfeld B, Kornblith AB, Gibson C, Scher HI, Curley-Smart T, Holland JC, Breitbart W: The memorial anxiety scale for prostate cancer: validation of a new scale to measure anxiety in men with with prostate cancer. Cancer 2003, 97(11):2910-2918.
• [42]Sundin EC, Horowitz MJ: Impact of Event Scale: psychometric properties. Br J Psychiatry 2002, 180:205-209.
• [43]Reddy S, Bruera E, Pace E, Zhang K, Reyes-Gibby CC: Clinically important improvement in the intensity of fatigue in patients with advanced cancer. J Palliat Med 2007, 10(5):1068-1075.
• [44]Cramp F, Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008, 16(2):CD006145.
• [45]Beck SL, Schwartz AL, Towsley G, Dudley W, Barsevick A: Psychometric evaluation of the Pittsburgh Sleep Quality Index in cancer patients. J Pain Symptom Manage 2004, 27(2):140-148.
• [46]Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28(2):193-213.
• [47]Newton RU, Hakkinen K, Hakkinen A, McCormick M, Volek J, Kraemer WJ: Mixed-methods resistance training increases power and strength of young and older men. Med Sci Sports Exerc 2002, 34(8):1367-1375.
• [48]Cheng S, Sipila S, Taaffe DR, Puolakka J, Suominen H: Change in bone mass distribution induced by hormone replacement therapy and high-impact physical exercise in post-menopausal women. Bone 2002, 31(1):126-135.
• [49]Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM: Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005, 90(12):6410-6417.
• [50]Holmes-Walker DJ, Woo H, Gurney H, Do VT, Chipps DR: Maintaining bone health in patients with prostate cancer. Med J Aust 2006, 184(4):176-179.
• [51]Eckert AW, Maurer P, Meyer L, Kriwalsky MS, Rohrberg R, Schneider D, Bilkenroth U, Schubert J: Bisphosphonate-related jaw necrosis–severe complication in maxillofacial surgery. Cancer Treat Rev 2007, 33(1):58-63.
• [52]Taaffe DR, Pruitt L, Pyka G, Guido D, Marcus R: Comparative effects of high- and low-intensity resistance training on thigh muscle strength, fiber area, and tissue composition in elderly women. Clin Physiol 1996, 16(4):381-392.